Extended duration of immunity for FeLV vaccines

Virbac has announced an extended duration of immunity has been granted by the European Medicines Agency for the feline leukaemia component of both Leucogen and Leucofeligen vaccines.

As a result of this extended duration of immunity, following the primary course and first annual booster, the FeLV component is only required every three years.

Annual boosters against feline rhinotracheitis calicivirus and panleucopenia can be provided during the intermediate years with Feligen RCP.

Leucogen is the world’s first recombinant subunit vaccine containing purified p45 FeLV-envelope antigen. Leucofeligen is a fully authorised combination vaccine for FeLV, rhinotracheitis, calicivirus and feline panleucopaenia virus.